FAQs

The choice between gene knockdown and knockout depends on both the characteristics of the target gene and the research objective. If preliminary experiments suggest that complete knockout may cause growth arrest or cell lethality, gene knockdown is recommended to obtain a viable and informative cell model. In contrast, when the target protein remains functionally active after knockdown, or when the gene is located in a non-coding region or is highly transcribed and difficult to suppress, gene knockout represents a more definitive and reliable approach.

We offer a diverse range of technical platforms to meet the precise requirements of different projects. For gene knockout (KO) projects, we commonly use CRISPR RNP complexes, lentiviral delivery, or plasmid-based strategies to ensure efficient editing. For gene overexpression, high-capacity PiggyBac transposon systems or stable, high-efficiency lentiviral transduction are preferred.

We understand that each method has its unique advantages, so the final strategy is fully tailored based on your gene of interest, cell background, and specific research objectives. If you have preferences or ideas regarding the technical approach, we welcome your input to collaboratively determine the optimal construction strategy.

Yes. The reporter genes are permanently integrated into the genome and selected using antibiotics, allowing stable passaging and consistent reporter expression.

We provide comprehensive and flexible stable cell line customization services tailored to your specific research needs. These include:

Gene knockout (KO)

Gene knock-in (KI)

Gene overexpression (OE)

RNA interference-mediated gene knockdown (KD)

Various reporter gene cell lines, such as fluorescent proteins (GFP/RFP) or luciferase reporters

Our scientific team collaborates closely with you to design the most suitable solution for your project.

Before initiating a stable cell line construction project, we typically require the following key information for accurate design and evaluation: the target gene (preferably an NCBI RefSeq ID or the full CDS sequence), the host cell line, and the specific project goal (e.g., overexpression, reporter gene, or gene knock-in). For knock-in projects, providing the intended genomic integration site (such as the AAVS1 safe harbor locus) can significantly streamline and optimize the design process.

Collect cells when they are in optimal condition and near the end of the logarithmic growth phase. Use an appropriate cryoprotectant and employ controlled-rate freezing, such as placing vials in a specialized freezing container to ensure a stable cooling rate. Once at −80 °C, transfer the vials as soon as possible to liquid nitrogen or another insulated container to maintain temperatures below −130 °C.

Slow growth may be inherent to the cell line (noted in technical documents). Other possible causes include incorrectly prepared or improperly stored culture medium, overly alkaline medium pH, cell senescence due to excessive passaging, abnormal incubator temperature or CO₂ levels, and contamination.

Each vial contains over 1 million cells.

Some RNA products are available as ready-to-use. Alternatively, customers can obtain RNA using commercially available extraction kits.